[go: up one dir, main page]

MX376047B - Inhibidores de desmetilasa-1 especifica de lisina. - Google Patents

Inhibidores de desmetilasa-1 especifica de lisina.

Info

Publication number
MX376047B
MX376047B MX2016007585A MX2016007585A MX376047B MX 376047 B MX376047 B MX 376047B MX 2016007585 A MX2016007585 A MX 2016007585A MX 2016007585 A MX2016007585 A MX 2016007585A MX 376047 B MX376047 B MX 376047B
Authority
MX
Mexico
Prior art keywords
cancer
compositions
compounds
lysine
specific demethylase
Prior art date
Application number
MX2016007585A
Other languages
English (en)
Other versions
MX2016007585A (es
Inventor
James Marvin Veal
Jeffrey Alan Stafford
Stephen W Kaldor
Toufike Kanouni
Young K Chen
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2016007585A publication Critical patent/MX2016007585A/es
Publication of MX376047B publication Critical patent/MX376047B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona generalmente a composiciones y métodos para tratar cáncer y enfermedad neoplásica. Se proporcionan en la presente compuestos derivados heterocíclicos sustituidos y composiciones farmacéuticas que comprenden los compuestos. Los presentes compuestos y composiciones son útiles para la inhibición de desmetilasa-1 específica de lisina. Además, los presentes compuestos y composiciones son útiles para el tratamiento de cáncer, tal como cáncer de próstata, cáncer de mama, cáncer de vejiga, cáncer de pulmón y/o melanoma, y los similares.
MX2016007585A 2013-12-11 2014-12-10 Inhibidores de desmetilasa-1 especifica de lisina. MX376047B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914927P 2013-12-11 2013-12-11
PCT/US2014/069562 WO2015089192A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Publications (2)

Publication Number Publication Date
MX2016007585A MX2016007585A (es) 2016-12-16
MX376047B true MX376047B (es) 2025-03-07

Family

ID=53371806

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007585A MX376047B (es) 2013-12-11 2014-12-10 Inhibidores de desmetilasa-1 especifica de lisina.
MX2020010496A MX2020010496A (es) 2013-12-11 2016-06-09 Inhibidores de desmetilasa-1 especifica de lisina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010496A MX2020010496A (es) 2013-12-11 2016-06-09 Inhibidores de desmetilasa-1 especifica de lisina.

Country Status (17)

Country Link
US (3) US9944636B2 (es)
EP (2) EP3080100B1 (es)
JP (1) JP6430512B2 (es)
CA (2) CA3161836A1 (es)
DK (1) DK3080100T3 (es)
ES (1) ES2935746T3 (es)
FI (1) FI3080100T3 (es)
HR (1) HRP20230086T1 (es)
HU (1) HUE061252T2 (es)
LT (1) LT3080100T (es)
MX (2) MX376047B (es)
PL (1) PL3080100T3 (es)
PT (1) PT3080100T (es)
RS (1) RS63939B1 (es)
SI (1) SI3080100T1 (es)
SM (1) SMT202300014T1 (es)
WO (1) WO2015089192A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691594A1 (ru) 2014-02-13 2017-02-28 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
BR112016025248B1 (pt) 2014-05-01 2022-12-13 Celgene Quanticel Research, Inc Compostos inibidores de demetilase lisina-específica-1, composição farmacêutica e seus usos
HUE050564T2 (hu) 2014-06-27 2020-12-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibitorai
BR112017000043A2 (pt) * 2014-07-03 2018-07-17 Celgene Quanticel Research, Inc. inibidores da desmetilase específica de lisina-1
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
ES2935114T3 (es) * 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
JP6510068B2 (ja) * 2015-11-27 2019-05-08 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
CA3009805C (en) 2015-12-29 2023-10-17 Mirati Therapeutics, Inc. Lsd1 inhibitors
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EP3430015A1 (en) 2016-03-16 2019-01-23 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
CN105924397B (zh) * 2016-04-29 2017-11-24 河南省农业科学院植物保护研究所 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
JP7352284B2 (ja) * 2017-05-15 2023-09-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
EP3632897A4 (en) 2017-05-26 2020-10-21 Taiho Pharmaceutical Co., Ltd. NEW BIPHENYL COMPOUND OR SALT OF THE SAME
KR102365342B1 (ko) * 2017-05-26 2022-02-23 다이호야쿠힌고교 가부시키가이샤 신규 비페닐 화합물을 사용한 항종양 효과 증강제
MA50518A (fr) 2017-05-31 2020-09-09 Taiho Pharmaceutical Co Ltd Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
DK3661510T3 (da) 2017-08-03 2025-01-02 Oryzon Genomics Sa Fremgangsmåder til behandling af adfærdsændringer
TWI794294B (zh) 2017-09-13 2023-03-01 南韓商韓美藥品股份有限公司 吡唑衍生化合物及其用途
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
EP4522137A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
CN119546292A (zh) 2022-05-09 2025-02-28 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US7291630B2 (en) * 2002-03-28 2007-11-06 Eisai Co., Ltd. Azaindoles as inhibitors of c-Jun N-terminal kinases
CA2507100C (en) 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
WO2007006581A2 (en) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
CA2640398A1 (en) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
HUE029188T2 (en) * 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
MX2011000729A (es) * 2008-07-29 2011-03-15 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2258865A1 (en) * 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
EP2258858A1 (en) * 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
WO2011022489A2 (en) 2009-08-18 2011-02-24 The Johns Hopkins University (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2598480B1 (en) * 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
GB201106829D0 (en) * 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
US9289415B2 (en) * 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
AR088351A1 (es) * 2011-10-31 2014-05-28 Lilly Co Eli Analogos de pirazol sustituidos
JP6209593B2 (ja) * 2012-05-04 2017-10-04 サミュメッド リミテッド ライアビリティ カンパニー １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用
JP6195828B2 (ja) * 2012-05-24 2017-09-13 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子

Also Published As

Publication number Publication date
PT3080100T (pt) 2023-01-19
CA2933480A1 (en) 2015-06-18
HRP20230086T1 (hr) 2023-03-31
US10385051B2 (en) 2019-08-20
US20190055242A1 (en) 2019-02-21
EP4257591A2 (en) 2023-10-11
CA2933480C (en) 2022-08-23
MX2020010496A (es) 2020-10-28
US20160304516A1 (en) 2016-10-20
EP3080100A4 (en) 2017-09-06
CA3161836A1 (en) 2015-06-18
RS63939B1 (sr) 2023-02-28
US20180179204A1 (en) 2018-06-28
US9944636B2 (en) 2018-04-17
MX2016007585A (es) 2016-12-16
SI3080100T1 (sl) 2023-04-28
EP3080100B1 (en) 2022-11-30
WO2015089192A1 (en) 2015-06-18
JP6430512B2 (ja) 2018-11-28
EP3080100A1 (en) 2016-10-19
DK3080100T3 (da) 2023-02-06
HUE061252T2 (hu) 2023-05-28
EP4257591A3 (en) 2023-11-22
ES2935746T3 (es) 2023-03-09
LT3080100T (lt) 2023-02-27
PL3080100T3 (pl) 2023-03-06
JP2017502940A (ja) 2017-01-26
FI3080100T3 (fi) 2023-03-15
SMT202300014T1 (it) 2023-05-12
US10131664B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
MX376047B (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX376207B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX375219B (es) Inhibidores de histona demetilasa.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX2017003464A (es) Inhibidores de histona desmetilasa.
MX2017003463A (es) Inhibidores de histona desmetilasa.

Legal Events

Date Code Title Description
FG Grant or registration